IL322449A - Synthesis of Bruton tyrosine kinase inhibitor - Google Patents
Synthesis of Bruton tyrosine kinase inhibitorInfo
- Publication number
- IL322449A IL322449A IL322449A IL32244925A IL322449A IL 322449 A IL322449 A IL 322449A IL 322449 A IL322449 A IL 322449A IL 32244925 A IL32244925 A IL 32244925A IL 322449 A IL322449 A IL 322449A
- Authority
- IL
- Israel
- Prior art keywords
- formula
- compound
- ibrutinib
- prop
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562103507P | 2015-01-14 | 2015-01-14 | |
| PCT/US2016/013424 WO2016115356A1 (en) | 2015-01-14 | 2016-01-14 | Synthesis of a bruton's tyrosine kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL322449A true IL322449A (en) | 2025-09-01 |
Family
ID=56406389
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL322449A IL322449A (en) | 2015-01-14 | 2016-01-14 | Synthesis of Bruton tyrosine kinase inhibitor |
| IL308276A IL308276A (en) | 2015-01-14 | 2016-01-14 | Synthesis of a proton tyrosine kinase inhibitor |
| IL253020A IL253020A0 (en) | 2015-01-14 | 2017-06-19 | Synthesis of a proton tyrosine kinase inhibitor |
| IL274716A IL274716A (en) | 2015-01-14 | 2020-05-17 | Synthesis of a proton tyrosine kinase inhibitor |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308276A IL308276A (en) | 2015-01-14 | 2016-01-14 | Synthesis of a proton tyrosine kinase inhibitor |
| IL253020A IL253020A0 (en) | 2015-01-14 | 2017-06-19 | Synthesis of a proton tyrosine kinase inhibitor |
| IL274716A IL274716A (en) | 2015-01-14 | 2020-05-17 | Synthesis of a proton tyrosine kinase inhibitor |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US20180009814A1 (enExample) |
| EP (1) | EP3245208A4 (enExample) |
| JP (2) | JP2018502077A (enExample) |
| KR (1) | KR20170102887A (enExample) |
| CN (2) | CN107108640A (enExample) |
| AU (2) | AU2016206693A1 (enExample) |
| BR (1) | BR112017015206B1 (enExample) |
| CA (2) | CA2971460C (enExample) |
| HK (1) | HK1246293A1 (enExample) |
| IL (4) | IL322449A (enExample) |
| MA (1) | MA41350A (enExample) |
| MX (2) | MX366827B (enExample) |
| RU (1) | RU2017128308A (enExample) |
| SG (2) | SG11201705678YA (enExample) |
| WO (1) | WO2016115356A1 (enExample) |
| ZA (1) | ZA201704338B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2712440C2 (ru) * | 2015-02-12 | 2020-01-29 | Шанхай Дьюд Медикал Сайенс Энд Текнолоджи Ко., Лтд | Способ получения ибрутиниба |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| KR20250007056A (ko) | 2016-03-04 | 2025-01-13 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| CN109206426B (zh) * | 2017-07-06 | 2021-10-08 | 上海复星星泰医药科技有限公司 | 吡唑并嘧啶类化合物的制备方法 |
| CN110944999A (zh) | 2017-08-01 | 2020-03-31 | 勃林格殷格翰国际有限公司 | 中间体化合物和方法 |
| CN107814804A (zh) * | 2017-10-27 | 2018-03-20 | 广州科锐特生物科技有限公司 | 依鲁替尼的制备方法 |
| US11833151B2 (en) | 2018-03-19 | 2023-12-05 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
| BR112020022185A2 (pt) | 2018-05-03 | 2021-02-02 | Juno Therapeutics Inc | terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase |
| JP6944496B2 (ja) | 2018-10-22 | 2021-10-06 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体 |
| AU2018448845B2 (en) | 2018-11-09 | 2022-03-24 | Taiho Pharmaceutical Co., Ltd. | Method for producing dimethoxybenzene compound |
| CN109988175A (zh) * | 2019-04-28 | 2019-07-09 | 梯尔希（南京）药物研发有限公司 | 一种依鲁替尼-d5的制备方法 |
| KR20220011669A (ko) | 2019-05-21 | 2022-01-28 | 얀센 파마슈티카 엔.브이. | Btk 억제제 제조를 위한 방법 및 중간체 |
| JP7658916B2 (ja) * | 2019-05-21 | 2025-04-08 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｂｔｋ阻害剤を調製するためのプロセス及び中間体 |
| US20240092785A1 (en) | 2021-01-21 | 2024-03-21 | Synthon B.V. | Process for making ibrutinib |
| CN114853662B (zh) * | 2021-02-05 | 2024-01-12 | 四川青木制药有限公司 | 手性肼基哌啶衍生物的制备方法 |
| US20250302954A1 (en) | 2022-05-11 | 2025-10-02 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2023242384A1 (en) | 2022-06-17 | 2023-12-21 | Krka, D.D., Novo Mesto | Crystalline form of ibrutinib |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4550214A (en) * | 1981-01-05 | 1985-10-29 | Polaroid Corporation | Blocked vinyl biphenyl compounds |
| US4874822A (en) * | 1988-04-07 | 1989-10-17 | Minnesota Mining And Manufacturing Company | Process for the acrylamidoacylation of alcohols |
| EP2228369A1 (en) * | 2003-12-23 | 2010-09-15 | Astex Therapeutics Ltd. | Pyrazole derivatives as protein kinase modulators |
| EP2529621B1 (en) * | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| EP2139487B1 (en) * | 2007-03-28 | 2015-11-11 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| US7741330B1 (en) * | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| CA2879400A1 (en) * | 2012-07-30 | 2014-02-06 | Concert Pharmaceuticals, Inc. | Deuterated ibrutinib |
| CN103121999A (zh) * | 2012-08-29 | 2013-05-29 | 苏州迪飞医药科技有限公司 | 一种酪氨酸激酶抑制剂pci-32765的合成方法 |
| US9156847B2 (en) * | 2013-03-15 | 2015-10-13 | Janssen Pharmaceutica Nv | Processes and intermediates for preparing a medicament |
| US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| CN103626774B (zh) * | 2013-11-20 | 2015-11-04 | 苏州明锐医药科技有限公司 | 伊鲁替尼的制备方法 |
| CN105471823B (zh) * | 2014-09-03 | 2018-10-26 | 阿里巴巴集团控股有限公司 | 一种敏感信息处理方法、装置、服务器及安全判定系统 |
| US10266535B2 (en) * | 2015-01-21 | 2019-04-23 | Hefei Institutes Of Physical Science, Chinese Academy Of Sciences | Inhibitor of FLT3 kinase and use thereof |
-
2016
- 2016-01-13 MA MA041350A patent/MA41350A/fr unknown
- 2016-01-14 MX MX2017009154A patent/MX366827B/es active IP Right Grant
- 2016-01-14 BR BR112017015206-1A patent/BR112017015206B1/pt active IP Right Grant
- 2016-01-14 IL IL322449A patent/IL322449A/en unknown
- 2016-01-14 WO PCT/US2016/013424 patent/WO2016115356A1/en not_active Ceased
- 2016-01-14 SG SG11201705678YA patent/SG11201705678YA/en unknown
- 2016-01-14 CA CA2971460A patent/CA2971460C/en active Active
- 2016-01-14 MX MX2019008815A patent/MX394327B/es unknown
- 2016-01-14 CA CA3210320A patent/CA3210320A1/en active Pending
- 2016-01-14 KR KR1020177019206A patent/KR20170102887A/ko not_active Ceased
- 2016-01-14 US US15/542,848 patent/US20180009814A1/en not_active Abandoned
- 2016-01-14 RU RU2017128308A patent/RU2017128308A/ru not_active Application Discontinuation
- 2016-01-14 CN CN201680005456.4A patent/CN107108640A/zh active Pending
- 2016-01-14 HK HK18105861.5A patent/HK1246293A1/zh unknown
- 2016-01-14 IL IL308276A patent/IL308276A/en unknown
- 2016-01-14 EP EP16737886.8A patent/EP3245208A4/en not_active Withdrawn
- 2016-01-14 JP JP2017532649A patent/JP2018502077A/ja active Pending
- 2016-01-14 SG SG10201906517VA patent/SG10201906517VA/en unknown
- 2016-01-14 CN CN202110485400.6A patent/CN113816962A/zh active Pending
- 2016-01-14 AU AU2016206693A patent/AU2016206693A1/en not_active Abandoned
-
2017
- 2017-06-19 IL IL253020A patent/IL253020A0/en unknown
- 2017-06-26 ZA ZA2017/04338A patent/ZA201704338B/en unknown
-
2018
- 2018-12-18 US US16/224,425 patent/US20190367518A1/en not_active Abandoned
-
2019
- 2019-12-04 US US16/703,344 patent/US20200347064A1/en not_active Abandoned
-
2020
- 2020-05-17 IL IL274716A patent/IL274716A/en unknown
- 2020-09-11 AU AU2020230323A patent/AU2020230323A1/en not_active Abandoned
- 2020-10-09 JP JP2020171454A patent/JP2021035947A/ja active Pending
-
2021
- 2021-02-17 US US17/177,852 patent/US20220098200A1/en not_active Abandoned
-
2023
- 2023-06-14 US US18/209,939 patent/US20240158400A1/en not_active Abandoned
-
2024
- 2024-07-24 US US18/782,878 patent/US20250197404A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240158400A1 (en) | Synthesis of a bruton's tyrosine kinase inhibitor | |
| IL310338A (en) | Production method for synthetic intermediate of monocyclic pyridine derivative | |
| IL284690B (en) | Process for preparing btk inhibitors | |
| TWI853704B (zh) | Lpa受體拮抗劑及其用途 | |
| AU2023254866B2 (en) | Compounds and compositions for treating conditions associated with APJ receptor activity | |
| IL296750A (en) | Pyrrolo[2,3-f]indazole and 2,4,5,10-tetrazatricyclo[7.3.0.03,7]dodeca-1,3(7),5,8,11-pentaene derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (aatd) | |
| EP2426135A1 (en) | Urea derivative having pi3k inhibitory activity | |
| KR20150021070A (ko) | 피롤로[2,3-b]피리딘의 합성 | |
| CN110041333B (zh) | 溴结构域抑制剂化合物及其用途 | |
| IL270068B (en) | Methods of manufacturing of niraparib | |
| IL297457A (en) | Ring closing synthesis of macrocyclic mcl-1 inhibitor intermediates | |
| IL268683B (en) | Processes for preparing ag-10, its intermediates, and salts thereof | |
| CN116897149A (zh) | 一种连接基药物偶联物的制备方法及其中间体 | |
| IL291114B2 (en) | Pyrimidine compound and method for preparing same | |
| IL314714A (en) | Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators | |
| EP3334735B1 (en) | Processes for preparing an fgfr inhibitor | |
| KR100399798B1 (ko) | 신규나프티리딘유도체 | |
| IL274773B2 (en) | A pyrimidine sulfamide derivative and a method of its preparation and medical application | |
| IL300979A (en) | STING gene interferon stimulator agonists | |
| IL297645B1 (en) | Synthesis of heterocyclic compounds | |
| WO2012051450A1 (en) | Method of making azaindazole derivatives | |
| IL266659A (en) | Fgfr4 inhibitor and preparation method and use thereof | |
| EP4370517B1 (en) | Synthesis of chiral substituted pyrazolopyrimidine compounds | |
| IL292328A (en) | Amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane salts and methods of making the same | |
| IL292327A (en) | Crystalline solids of 3-palmitoyl-amido-2,1-propanediol and 3-palmitoyl-amido-2-hydroxy-1-dimethoxytrinylmethylether-propane and methods for their preparation and use |